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models as obstacles to equity of access to HCDs. They were con-
cerned that there were inequities in decisions for individual
patients depending on public or private sector hospital status.
Tertiary public hospitals were perceived to be at the ‘cutting
edge’ and therefore were required to fund new, expensive drugs.
A major concern for respondents was that, as a consequence, this
meant prioritizing between patient groups and individual cases.
“Why is one patient group more important than another patient
group and how do we decide which drugs should be available
to each patient?” The majority of respondents identiﬁed equity
problems in access to HCDs, however they had difﬁculty in iden-
tifying solutions. Respondents described that, besides safety,
effectiveness, efﬁcacy and cost, ethical principles should be borne
in mind when deciding whether a HCD should be available in a
public hospital. Most wanted a transparent, accountable, evi-
dence-based decision-making process. CONCLUSION: The pre-
liminary results of this study suggest that decision-makers were
concerned about the equity of access to HCDs in public hospi-
tals. They were concerned regarding the process for decision-
making and the outcomes of these decisions. Further research
will explore the views of the public regarding funded access to
HCDs.
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AIM: To perform a comparative examination of the drug reim-
bursement systems in 16 secondary markets in Central and
Eastern Europe, Africa, and Middle East. METHODS: The
results of this study are derived from published literature and
through interviews with key opinion leaders and reimbursement
ofﬁcials in each of the 16 countries. The reimbursement system
in each country is assessed by using a set of predeﬁned criteria.
Speciﬁcally, the criteria aim to investigate whether there is public
reimbursement of pharmaceuticals in the country, to identify
whether a formalised review process for reimbursement applica-
tion exists, whether or not a pharmacoeconomic evaluation is
required in the reimbursement application, and to determine if
a reference pricing system is implemented in price determination
for new pharmaceuticals. These criteria will allow an under-
standing of the types of reimbursement systems in these 
countries and identiﬁes trends in drug reimbursement policy.
RESULTS: A majority of the countries considered in this study
had some form of public reimbursement system for pharmaceu-
ticals. Notable exceptions include middle-eastern countries
where reimbursement is restricted to inpatients, while private
health insurance is more prevalent in countries like South Africa
and Russia. Very few countries, however, have an established
formal reviewing system for reimbursement applications. Refer-
ence pricing was common in these markets. Several countries are
in the process of introducing formal pharmacoeconomic require-
ments. CONCLUSION: The main concern of reimbursement
authorities in these countries is containment of increasing drug
costs. Several countries are increasingly formalizing this process.
HR4
IMPACT OF MEMBER COST-SHARING LEVELS ON
POPULATION-BASED STATIN USE RATES
Moore JM, Xiao JQ, Marks A
Caremark, Inc, Northbrook, IL, USA
OBJECTIVE: Numerous studies have found that substantial
increases in drug co-payments result in reductions in utilization
and spending. A recent study found that signiﬁcantly more
members faced with substantially increased costs stopped statin
therapy than a control group. High co-payments can inﬂuence
the decision to start needed drug therapy as well as to discon-
tinue it. This study analyzes population-based statin use rates as
one way to look at the impact of high cost sharing on the deci-
sion to start therapy as well as to continue statin therapy.
METHODS: The study included 15,937 statin users in 16
employer groups with average member cost share greater than
30% (HIGH) and 86,605 statin users in 48 employer groups
with member share less than 15%. Employer groups with DAW
penalties were excluded. LOW and HIGH share groups both had
retail and mail coverage. Drug utilization and group eligibility
data for 2003 came from Caremark Rx claims data system.
HIGH and LOW groups were compared on age and gender. Age-
speciﬁc population use rates were computed for 12 ﬁve-year age
bands between 30 and 89. RESULTS: Age-speciﬁc population-
based use rates for the HIGH share group averaged only 79%
of the level of the LOW share group. For example, the statin use
rate for 60–64 years of age was 279.1 per 1000 for the HIGH
share group and 359.8 per 1000 for the LOW share group.
CONCLUSIONS: High levels of member cost sharing impact
population-based statin use rates. Additional educational efforts
may be necessary to encourage use of preventive health care 
as members assume greater responsibility for the costs of 
medication.
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OBJECTIVE: Since 1992, pharmacoeconomic guidelines, which
contain speciﬁc costing recommendations, have been available
yet reviews of recent economic evaluations indicate that investi-
gators are still using a wide range of methods. This discourages
uniformity of results. Two possible reasons for this are 1) insuf-
ﬁcient detail in the recommended guidelines and 2) a lack of stan-
dardization. We conducted a comparative review of national
costing guidelines to determine the degree of detail provided 
in the guidelines and the degree of correspondence. The main
purpose was to develop a more comprehensive framework.
METHODS: Guidelines were identiﬁed and reviewed. A frame-
work with categories were developed, and all guidelines were
reviewed in light of these categories. RESULTS: Our framework
contained the following headings: General items, Resource iden-
tiﬁcation and classiﬁcation, Resource measurement, Resource
Valuation, and reporting cost per patient. Our review of guide-
lines indicated that major differences arose because of different
study purposes (studies conducted for formal formulary submis-
sions versus general purpose studies). Other differences between
the stated guidelines resulted from analytical differences in
costing analysis, in areas such as lifetime unrelated costs and lost
productivity costs. We also found an absence of detail in the
costing recommendations. CONCLUSIONS: Both with regard
to resource measurement and resource valuation categories, very
little conceptual guidance relating to the basic cost measure was
provided, and no systematic recommendations emerged with
regard to inter-temporal and geographical adjustments to the
basic cost measure. A more detailed set of recommendations is
proposed.
